Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial.
<h4>Importance and objective</h4>The aim of this pragmatic, embedded, adaptive trial was to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of inpatients with moderate to severe COVID-1...
Saved in:
Main Authors: | Westyn Branch-Elliman, Ryan Ferguson, Gheorghe Doros, Patricia Woods, Sarah Leatherman, Judith Strymish, Rupak Datta, Rekha Goswami, Matthew D Jankowich, Nishant R Shah, Thomas H Taylor, Sarah T Page, Sara J Schiller, Colleen Shannon, Cynthia Hau, Maura Flynn, Erika Holmberg, Karen Visnaw, Rupali Dhond, Mary Brophy, Paul A Monach |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263591&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study
by: Kaitlin Swinnerton, et al.
Published: (2025-01-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders
by: Yoshifumi Tada, et al.
Published: (2023-01-01) -
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
by: Gerd R Burmester, et al.
Published: (2019-10-01) -
Evaluating Meaningful Changes in Patient‐Reported Outcome Measurement Information System–Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Patients With Rheumatoid Arthritis
by: Clifton O. Bingham, et al.
Published: (2025-01-01)